Cite
MLA Citation
T. Wang et al.. “82P Preliminary analysis of tislelizumab (TIS) and chemotherapy as neoadjuvant therapy for potentially resectable stage IIIA/IIIB non-small cell lung cancer (NSCLC).” Immuno-oncology technology, vol. 16, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100172206853.0x00000b